Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: 1

Phase: NA

Enrollment: 7000

Sponsor: Sinovac Life Sciences Co., Ltd.

Summary

This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.

Eligibility Criteria

Inclusion Criteria:Medical staff working in the designated COVID-19 hospitals and Fangcang shelter hospitals (alternate care sites) of COVID-19 cases in Hohhot;Subjects were 18 years of age and older and in good health;Subjects volunteered to use COVID-19 neutralizing antibody nasal spray.Exclusion Criteria:Previous history of severe allergies or sensitivity to inhaled allergens;Women were pregnant or breastfeeding;Subjects were unable to cooperate with nasal spray inhalation;Other conditions for which medication was not appropriate.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05664919). StuddyBuddy aggregates publicly available trial information.